News
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
Pentixapharm Holding AG completes rights offering and private placement, raising EUR 20.4 million for PANDA Phase 3 trial, US market expansion, and CXCR4-based theranostic platform development -
-
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement
Pentixapharm Holding AG successfully completes rights offering and offers remaining shares through private placement for capital increase. Gross proceeds of EUR 16.8 million -
-
PRESS RELEASE
Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY
Research report on Pentixapharm Holding AG by NuWays AG highlights the potential breakthrough in diagnostic market with PentixaFor, a non-invasive PET scan for primary aldosteronism. Buy recommendation and target price of EUR 7.2 -
-
PRESS RELEASE
Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism
Pentixapharm Holding AG granted FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor diagnostic candidate in primary aldosteronism. Fast Track streamlines regulatory process & interaction with FDA
